

IN THE UNITED STATES DISTRICT COURT  
FOR THE DISTRICT OF DELAWARE

BOEHRINGER INGELHEIM	)	
INTERNATIONAL GMBH and BOEHRINGER	)	
INGELHEIM PHARMACEUTICALS, INC.,	)	
	)	
Plaintiffs,	)	C.A. No. 05-700 (JJF)
	)	CONSOLIDATED
v.	)	
	)	
BARR LABORATORIES, INC.	)	
	)	
Defendant.	)	
	)	
	)	
BOEHRINGER INGELHEIM	)	
INTERNATIONAL GMBH and BOEHRINGER	)	C.A. No. 05-854 (JJF)
INGELHEIM PHARMACEUTICALS, INC.,	)	
	)	
Plaintiffs,	)	
	)	
v.	)	
	)	
MYLAN PHARMACEUTICALS, INC.,	)	
	)	
Defendant.	)	

**PLAINTIFFS' TRIAL EXHIBIT LIST**

OF COUNSEL:  
Steven C. Cherny  
LATHAM & WATKINS LLP  
885 Third Avenue, Suite 1000  
New York, NY 10022-4834  
(212) 906-1200

Kenneth G. Schuler  
Amanda J. Hollis  
LATHAM & WATKINS LLP  
Sears Tower, Suite 5800  
Chicago, IL 60606  
(312) 876-7700

MORRIS, NICHOLS, ARSHT & TUNNELL LLP  
Jack B. Blumenfeld (#1014)  
Maryellen Noreika (#3208)  
1201 North Market Street  
P. O. Box 1347  
Wilmington, DE 19899-1347  
(302) 658-9200  
jblumenfeld@mnat.com  
mnoreika@mnat.com

*Attorneys for Plaintiffs  
Boehringer Ingelheim International Gmb and  
Boehringer Ingelheim Pharmaceuticals, Inc.*

March 10, 2008

TX NO.	BATES	DATE	DESCRIPTION	ADMITTED
TX 3	BOE00000001- BOE00000015		U.S. Patent 4,886,812	
TX 9	BOE00849171- BOE00849178	06/26/84	Tatigkeitsbericht II/1984 (Quarterly Report)	
TX 35	BOE00849191- BOE00849203	09/20/84	Tatigkeitsbericht III/1984 (Quarterly Report)	
TX 40	BOE00849213- BOE00849224	12/17/84	Tatigkeitsbericht IV/1984 (Quarterly Report)	
TX 41	BOE00849164- BOE00849170	03/29/85	Tatigkeitsbericht I/1985 (Quarterly Report)	
TX 42	BOE00849179- BOE00849190	05/28/85	Tatigkeitsbericht II/1985 (Quarterly Report)	
TX 43	BOE00849225- BOE00849236	12/16/85	Tatigkeitsbericht IV/1985 (Quarterly Report)	
TX 46	BARR000065- BARR000427		U.S. Patent 4,731,374 File History	
TX 50	BOE00849204- BOE00849212	10/02/85	Tatigkeitsbericht III/1985 (Quarterly Report)	
TX 64	BARR194696- BARR194712	05/09/06	Analytical Method Validation Report Pramipexole Dihydrochloride Monohydrate Drug Substance – Enantiomeric Purity and Pramipexole Dihydrochloride Tablets, 0.125 mg, 0.25 mg, 0.5 mg, 1.0 mg, 1.0 mg and 1.5 mg - HPLC	
TX 99	BARR000615- BARR000925		U.S. Patent 4,886,812 File History	
TX 106	BOE00037394- BOE00037531	01/1993	Pramipexole in Parkinson's Disease Product Development Plan First Edition January, 1993	
TX 136	BARR015768- BARR015782	02/15/05	Pramipexole Dihydrochloride Tablets, 0.25 MG Bio-Committee Meeting Notes	
TX 139	BARR018656- BARR018664		Barr Labs Inc: Product Development Information Summary	
TX 142	BARR208390- BARR208455	10/15/04	E-mail to W. Kwok, E. Noble Gray from L. O'Dea re Pramipexole Dihydrochloride Monohydrate/Amino Chemicals Ltd. Technical Package	
TX 145	GYMA000001-	05/2004	Email with attachment of Amino: Pramipexole Technical Package	

TX NO.	BATES	DATE	DESCRIPTION	ADMITTED
	GYMA000030			
TX 146	GYMA000440- GYMA000490	09/01/04	Email to G. Yen, J. Kover, and S. Indahl from G. Yen enclosing Technical Dossier for Pramipexole	
TX 152	GYMA000495- GYMA000497	10/15/04	Email to J. Kover and G. Yen from S. Indahl re Pramipexole information request	
TX 153	GYMA000038	10/20/04	Email to S. Indahl from P. Munoz re Pramipexole/Amino	
TX 154	GYMA000063- GYMA000066	11/01/04	Email to S. Indahl from Gyma Administrative Office re attached letter re Pramipexole Dihydrochloride Monohydrate/Amino Chemicals Ltd.	
TX 157	BARR032187- BARR032190	03/02/06	Email to G. Yen, H. Prisco, E. Noble Gray, L. O'Dea and P. Costa from W. Kwok re attached list of requests for Amino re Pramipexole Dihydrochloride Monohydrate	
TX 206	BARR195178- BARR195180	05/01/06	Change Control for Finished Product Test Method & Specs Pramipexole Dihydrochloride Tablets, All Strengths 0 Update QC Specification Sheets and MTH-684	
TX 209	BARR022807- BARR023189		Excerpts from Abbreviated New Drug Application Chemistry, Manufacturing and Controls: Drug Substance	
TX 223		10/16/06	Notice of Deposition of Barr Laboratories, Inc. Pursuant to Fed. R.Civ.P. 30(b)(6)	
TX 227	BARR018493- BARR018651	01/09/06	Product Development Report for Pramipexole Dihydrochloride Tablets, 0.125 mg, 0.25 mg, 1 mg & 1.5 mg	
TX 228	BARR049897- BARR049925	05/20/04	Pramipexole Dihydrochloride Monohydrate Technical Package	
TX 229	BARR016120- BARR016168	07/2004	Pramipexole Dihydrochloride Monohydrate/Amino Chemicals Ltd. Technical Package	
TX 261	BARR142577- BARR142607	03/02/06	Investor Presentation	
TX 262		8/30/06	Barr Pharmaceuticals Inc. Form 10-k Annual Report	
TX 263	BARR014162- BARR014163	04/09/02	Filed 8/30/2006 for Period Ending 6/30/2006 Dopamine Agonists discussed as treatment option for Restless Legs Syndrome	
TX 264	BARR014167- BARR014168	11/27/02	Pramipexole now in Clinical Development for Restless Legs Syndrome indication	
TX 265	BARR014172-	04/30/04	Study Demonstrates Mirapex/Sifrol (pramipexole) induces Rapid Relief	

TX NO.	BATES	DATE	DESCRIPTION	ADMITTED
	BARR014173		from Restless Legs Syndrome	
TX 266	BARR014134- BARR014137	1999	Mirapex for Restless Legs Syndrome or Periodic Limb Movements of Sleep	
TX 275	BARR022395- BARR022398	05/26/05	Letter to Center for Drug Evaluation and Research from Barr re Abbreviated new drug application 0.25 mg	
TX 276	BARR026516- BARR026520	06/23/05	Letter to Center for Drug Evaluation and Research from Barr re: Abbreviated new drug application 0.125 mg, 0.5 mg, 1 mg, 1.5 mg	
TX 277	BARR042773- BARR042849		Abbreviated New Drug Application 0.25 mg Comparison between Generic Drug and Reference listed Drug	
TX 278	BARR0208826		Abbreviated New Drug Application: Bioequivalency Amendment to ANDA # 77-605	
TX 279	BARR194333- BARR194364		Pramipexole Tablets: 0.125 mg, 0.25 mg, 0.5 mg, 1 mg, 1.5 mg Product Development Report for Pramipexole Tablet 0.125 mg, 0.25 mg, 0.5 mg, 1 mg, 1.5 mg	
TX 281	BARR049063- BARR049112	08/18/04	Letter to S. Indahl from G. Yen re enclosed Pramipexole Dihydrochloride Monohydrate/Amino Chemicals Ltd. Technical Package	
TX 283	BARR020781- BARR020783	2/16/2006	Minor Amendment ANDA 77-724	
TX 284	BARR209163- BARR209239		Minor Amendment ANDA 77-724	
TX 286	BARR000428- BARR000614		Pramipexole Tablets 0.125 mg, 0.25 mg, 0.5 mg, 1 mg, and 1.5 mg U.S. Patent 4,843,086 File History	
TX 287			Alexander M. Klibanov CV	
TX 291			Excerpt of The Condensed Chemical Dictionary Tenth Edition	
TX 292		1976	Excerpt of the Merck Index Ninth Edition 1976	
TX 293		1983	Excerpt of the Merck Index Tenth Edition 1983	
TX 294		01/03/07	Letter to Kenneth Schuler from Jessamyn Berniker re proposed claim constructions for terms/phrases	
TX 295	BOE00001102- BOE00001201		Dr. Schneider's Lab Notebook	
TX 301	BOE0002910- BOE0002999		Spreadsheet	
TX 302	BOE00003087- BOE00003102		Prescription Spreadsheet	

TX NO.	BATES	DATE	DESCRIPTION	ADMITTED
TX 305	BOE00881507	02/2007	Performance Metrics Overview by Diagnoses	
TX 310	BARR209593		IMS Health National Disease & Therapeutic Index	
TX 311			National Institute of Neurological Disorders and Stroke Myoclonus Fact Sheet	
TX 312			ICD9DATA.COM website printout	
TX 313	BOE00002701- BOE00002721	01/27/06	Mirapex Weekly Report	
TX 314	BOE00677589- BOE00677614	10/28/05	Mirapex RLS 2006 Business Plan	
TX 315	BOE00806859- BOE00806914	10/10/05	U.S. Marketing Plan 2006 Mirapex – Parkinson’s Disease	
TX 326		8/07	Aiken, C., Pramipexole in Psychiatry: A Systematic Review of the Literature, J Clin Psychiatry 68:8, August 2007	
TX 400		12/11/06	Notice of Deposition of Mylan Pharmaceuticals, Inc. Pursuant to Fed.R.Civ. P. 30(b)(6)	
TX 401	MYL0000140	08/26/05	Letter from S. Talton to G. Buehler Regarding Mylan Certifications	
TX 402	MYL0000141		Table of Comparison	
TX 403	MYL0002296	07/01/04	Mylan Pharmaceuticals Inc. Phase II New Product Selection Product/Market Overview	
TX 404	MYL0002305		Mylan Pharmaceuticals Inc. 3 Year Plan	
TX 405	MYL0002297		Pramipexole (Mirapex) Pharmacia & Upjohn (Sales, Trends and Shares of Pramipexole)	
TX 406	BARR000011- BARR000020	09/12/05	Barr’s Notice Letter to Boehringer	
TX 407		03/02/06	Defendant Barr Laboratories, Inc.’s Responses to Plaintiffs Boehringer Ingelheim International GMBH and Boehringer Ingelheim Pharmaceutical, Inc.’s First Set of Interrogatories	
TX 408		06/22/06	Defendant Barr Laboratories, Inc.’s Responses to Plaintiffs Boehringer Ingelheim International GMBH and Boehringer Ingelheim Pharmaceutical, Inc.’s Second Set of Interrogatories	
TX 409		08/22/06	Defendant Barr Laboratories, Inc.’s Supplemental Responses to Plaintiffs Boehringer Ingelheim International GMBH and Boehringer Ingelheim Pharmaceutical, Inc.’s Interrogatories Nos. 3,4,5,8 and 10	
TX 410		09/11/06	Defendant Barr Laboratories, Inc.’s Responses to Plaintiffs Boehringer Ingelheim International GMBH and Boehringer Ingelheim Pharmaceutical, Inc.’s Third Set of Interrogatories	

TX NO.	BATES	DATE	DESCRIPTION	ADMITTED
TX 411		01/30/07	Defendant Barr Laboratories, Inc.'s Responses to Plaintiffs Boehringer Ingelheim International GMBH and Boehringer Ingelheim Pharmaceutical, Inc.'s Fourth Set of Interrogatories	
TX 411-A	BARR021827- BARR021837	5/26/05	New Product Launch Risk Analysis -- Active Supply Product: Pramipexole Dihydrochloride Tablets 0.25, 0.5, 1.0, 1.5, 0.125mg Brand: Mirapex (Boehringer Ingel) Submitted: 5/26/05	
TX 411-B	BARR021854- BARR021859		Chart: Assumptions Pramipexole Dihydrochloride Tablets 0.25, 0.5, 1.0, 1.5,	
TX 411-C	BARR060049- BARR060072		CI Filed Products Chart	
TX 411-D	BARR060076- BARR060080		Pramipexole Dihydrochloride API Cost Model	
TX 411-E	BARR060144- BARR060158	3/16/06	Pramipexole Dihydrochloride -- Validation and Launch Analysis	
TX 411-F	BARR064420- BARR064454	8/14/04	Strategic Business Development	
TX 411-G	BARR160507- BARR160512		7 Yr. Summary \$ - SherlockFY06	
TX 412		02/09/06	Defendant's Objections and Responses to Plaintiffs' First Set of Interrogatories to Mylan	
TX 413		10/16/06	Defendant's Supplemental Objections and Responses to Plaintiffs' First Set of Interrogatories to Mylan	
TX 414		10/16/06	Defendant's Objections and Responses to Plaintiffs' Second Set of Interrogatories to Mylan	
TX 415		10/16/06	Defendant's Objections and Responses to Plaintiffs' Third Set of Interrogatories to Mylan	
TX 416		01/08/07	Defendant's Objections and Responses to Plaintiffs' Fourth Set of Interrogatories to Mylan	
TX 417	MYL00002176- MYL00002212		Mylan's Proposed Product Label Insert	
TX 418	MYL0003931- MYL0003984		Mylan's Proposed Product Label for Pramipexole	
TX 419	BOE00881432- BOE00881467	11/07/06	Boehringer's Revised Product Label for Mirapex	

TX NO.	BATES	DATE	DESCRIPTION	ADMITTED
TX 420	BARR023323- BARR023341	05/2005	Barr's Proposed Product Label for Pramipexole	
TX 421	BARR027051- BARR027069	06/2005	Barr's Proposed Product Label for Pramipexole	
TX 422	BARR208788- BARR208806	08/2006	Barr's Revised Proposed Product Label for Pramipexole	
TX 423	BOE00881649- BOE00881817	06/24/85	Certified copy of 06/747,748 Eli Lilly Patent Application File History (Abandoned)	
TX 424		12/11/07	USPTO Website Printout: Patent Terms Extended Under 35 USC §156	
TX 425	BYR0000059	03/02/05	Email to Venkatesh from Kelley (for N. Cola) re Pramipexole/Mylan Pharmaceuticals	
TX 426	BOE00001351- BOE00001430	11/12/92	Agreement between Boehringer Ingelheim International GMBH and The Upjohn Co	
TX 427	BOE00001432- BOE00001449	07/02/97	Co-Promotion Agreement between Pharmacia & Upjohn Co and Boehringer Ingelheim Pharmaceuticals, Inc	
TX 428	BOE00001451- BOE00001457	07/14/97	Supply Agreement between Pharmacia & Upjohn Caribe, Inc. and Boehringer Ingelheim International GmbH	
TX 429	BOE00001481- BOE00001518	12/01/03	Toll Manufacturing Agreement Between Pfizer Inc. and Boehringer Ingelheim Pharmaceuticals, Inc.	
TX 430	BOE00000048- BOE00000051	03/06/06	Certified copy of Patent Assignment Records for 4,866,812, 4,843,086 and 4,731,374	
TX 431	BOE00000052- BOE00000053	03/06/06	Certified copy of Patent Assignment Records for D-7950	
TX 432	BOE00000054- BOE00000072		Patent Assignment Records	
TX 433	BOE00881818- BOE00881857	08/2007	Performance Metrics Overview by Diagnoses	
TX 434	BOE00881858- BOE00881897		PD Market: Mirapex NRxs (Factored for PD)	
TX 435	BOE00881898- BOE00881937	08/2007	Market Information: RLS Market: NRxs (Factored for RLS)	
TX 436	BOE00881348- BOE00881396	2007	Mirapex Parkinson's Disease Brand Plan	
TX 437			Curriculum Vitae of Charles Warren Olanow, M.D., F.R.C.P. (C)	
TX 438			Ehringer H, Hornykiewicz O. Distribution of noradrenalin and dopamine	

TX NO.	BATES	DATE	DESCRIPTION	ADMITTED
			(3-hydroxytyramine) in the human brain and their behavior in diseases of the extrapyramidal system. <i>Klin Wochenschr.</i> 960;38:1236-1239	
TX 439		2004	Olanow CW. The Scientific Basis for the Current Treatment of Parkinson's Disease. <i>Annu. Rev. Med.</i> 2004;55:41-60	
TX 440		1967	Cotzias GC, Van Woert MH, Schiffer LM. Aromatic amino acids and modification of parkinsonism. <i>New Engl. J. Med.</i> 1967;276:374-379	
TX 441		2004	Olanow CW, Agid Y, Mizuno Y, et al. Levodopa in the Treatment of Parkinson's Disease: Current Controversies. <i>Movement Disorders.</i> Vol. 19: No. 9, 2004, 997-1005	
TX 442		1974	Calne DB, Teychenne PF, Claveria LE et al. Bromocriptine in Parkinsonism. <i>Br. Med. J.</i> 1974; 4: 442-444	
TX 443		1998	Calne DB, Burton K, Beckman J, Martin WR. Dopamine Agonists and Neuroprotection in Parkinson's Disease. <i>Ann. Neurol.</i> 1998;44:S167-74	
TX 444		1992	Mierau J, Schingnitz G. Biochemical and pharmacological studies on pramipexole, a potent and selective dopamine D2 receptor agonist. <i>Eur J Pharmacol.</i> 1992;215:161-70	
TX 445	BOE00664295- BOE00664305	1998	Piercey MF. Pharmacology of Pramipexole, a Dopamine D3-Preferring Agonist Useful in Treating Parkinson's Disease. <i>Clin. Olanow Expert Report Appendix Neuropharmacol.</i> 1998;21:141-51	
TX 446		2007	Dewey RB 2nd, Reimold SC, O'Suilleabhain PE. Cardiac valve regurgitation with pergolide compared with nonergot agonists in Parkinson disease. <i>Arch Neurol.</i> 2007;64:377-80	
TX 447		1997	Parkinson Study Group. Safety and Efficacy of Pramipexole in Early Parkinson Disease. A Randomized Dose-Ranging Study. <i>JAMA.</i> 1997;278:125-30	
TX 448		1997	Lieberman A, Ranhosky A, Korts D. Clinical evaluation of pramipexole in advanced Parkinson's disease: results of a double-blind, placebo-controlled, parallel-group study. <i>Neurology.</i> 1997;49:162-8	
TX 449	BOE00640082- BOE00640087	1999	Pinter MM, Pogarell O, Oertel WH. Efficacy, safety, and tolerance of the non-ergoline dopamine agonist pramipexole in the treatment of advanced Parkinson's disease: a double-blind, placebo-controlled, randomized, multicentre study. <i>J Neurol, Neurosurg, Psychiatry.</i> 1999;66:436-441	



TX NO.	BATES	DATE	DESCRIPTION	ADMITTED
TX 450	BOE00640606- BOE00640613	1998	Wermuth L and the Danish Pramipexole Study Group. A double-blind, placebo-controlled, randomized, multi-center study of pramipexole in advanced Parkinson's disease. Eur. J. Neurol. 1998; 5:235-242	
TX 451	BOE00655728- BOE00655733	1997	Guttman M for the International Pramipexole-Bromocriptine Study Group. Double-blind comparison of pramipexole and bromocriptine treatment with placebo in advanced Parkinson's disease. Neurology 1997;49:1060-5	
TX 452		1999	Kunig G, Pogarell O, Moller JC, Delf M, Oertel WH. Pramipexole, a nonergot dopamine agonist, is effective against rest tremor in intermediate to advanced Parkinson's disease. Clin Neuropharmacol. 1999;22:301-5	
TX 453		2000	Parkinson Study Group. Pramipexole vs Levodopa as Initial Treatment for Parkinson Disease: A Randomized Controlled Trial. JAMA. 2000;284:1931-8	
TX 454		2001	Parkinson Study Group. Pramipexole vs Levodopa as Initial Treatment for Parkinson Disease: a 4-Year Randomized Controlled Trial. Arch Neurol. 2004;61:1044-53	
TX 455		2005	Olanow CW, Watts RL, Koller WC. An algorithm (decision tree) for the management of Parkinson's disease (2001): Treatment guidelines. Neurology 2001; 56:S1-S88	
TX 456		2005	Hely MA, Morris JG, Reid WG, Trafficante R. Sydney Multicenter Study of Parkinson's Disease: Non-L-Dopa-Responsive Problems Dominate at 15 Years. Mov. Disord. 2005;20:190-9	
TX 457		2004	Schapira AH, Olanow CW. Neuroprotection in Parkinson Disease: Mysteries, Myths, and Misconceptions. JAMA. 2004;291:358-64	
TX 458		2006	Suchowersky O, Gronseth G, et al. Practice Parameter: Neuroprotective strategies and alternative therapies for Parkinson disease (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2006;66:976-82	
TX 459		2005	Goetz CG, Poewe W, Rascol O, Sampaio C. Evidence-Based Medical Review Update: Pharmacological and Surgical Treatments of Parkinson's Disease: 2001 to 2004. Mov. Disord. 2005;20:523-39	

TX NO.	BATES	DATE	DESCRIPTION	ADMITTED
TX 460	BOE00711520- BOE00711544	2003	Schapira AHV, Olanow CW. Rationale for the use of dopamine agonists as neuroprotective agents in Parkinson's disease. <i>Ann. Neurol.</i> 2003; 53 (suppl 3): 149-159	
TX 461		1998	Olanow CW, Jenner P, Brooks D. Dopamine agonists and neuroprotection in Parkinson's disease. <i>Ann Neurol.</i> 1998 Sep.;44 (3 Suppl 1):S167-74	
TX 462		2001	Le Wei-Dong, Jankovic J. Are Dopamine Receptor Agonists Neuroprotective in Parkinson's Disease? <i>Drugs and Aging</i> 2001; 18(6)	
TX 463		1999	Zou L, Jankovic J, Rowe DB, et al. Neuroprotection by pramipexole against dopamine- and levodopa-induced cytotoxicity. <i>Life Sci.</i> 1999;64:1275-85	
TX 464		2002	Schapira AH. Dopamine agonists and neuroprotection in Parkinson's disease. <i>Eur. J. Neurol.</i> 2002;9 Suppl. 3:7-14	
TX 465		2006	Iravani MM, Haddon CO, Cooper JM, et al. Pramipexole protects against MPTP toxicity in non-human primates. <i>J. Neurochem.</i> 2006;96:1315-21	
TX 466		2000	Takata K, Kitamura Y, Kakimura J-I, et al. Increase of Bcl-2 protein in neuronal dendritic processes of cerebral cortex and hippocampus by the antiparkinsonian drugs, talipexole and pramipexole. <i>Brain Research.</i> 2000; 872: 236-241	
TX 467		2002	Parkinson Study Group. Dopamine Transporter Brain Imaging to Assess the Effects of Pramipexole vs Levodopa on Parkinson Disease Progression. <i>JAMA.</i> 2002;287:1653-61	
TX 468		2006	Schapira AH, Obeso J. Timing of Treatment Initiation in Parkinson's Disease: A Need for Reappraisal? <i>Ann. Neurol.</i> 2006;59:559-62	
TX 469		2004	Chaudhuri KR, Odin P, Olanow CW. Restless Legs Syndrome. Parthenon Publishing, London, 2004	
TX 470		2002	Comella CL. Restless legs syndrome: Treatment with dopaminergic agents. <i>Neurology.</i> 2002; 58 (Suppl 1):S87-92	
TX 471		2007	Oertel WH, Stiasny-Kolster K, Bergtholdt B, et al. Efficacy of Pramipexole in Restless Legs Syndrome: A Six-Week, Multicenter, Randomized, Double-Blind Study (Effect-RLS Study). <i>Mov. Disord.</i> 2007;22:213-9	

TX NO.	BATES	DATE	DESCRIPTION	ADMITTED
TX 472		2006	Winkelman JW, Sethi MD, Kushida CA, et al. Efficacy and safety of pramipexole in restless legs syndrome. Neurology. 2006; 67:1034-9	
TX 473	BOE00649837- BOE00649839	2003	Silber MH, Girish M, Izurieta R. Pramipexole in the Management of Restless Legs Syndrome: An Extended Study. Sleep. 2003;26(7):819-21	
TX 474	BOE00649804- BOE00649809	1999	Montplaisir J, Nicolas A, Denesle R, Gomez-Mancilla B. Restless legs syndrome improved by pramipexole: A double-blind randomized trial. Neurology. 1999;52:938-43	
TX 475		1998	Lin SC, Kaplan J, Burger CD, Fredrickson PA. Effect of Pramipexole in Treatment of Resistant Restless Legs Syndrome. Mayo Clin Proc. 1998;73:497-500	
TX 476		2006	Montplaisir J, Fantini ML, Desautels A, et al. Long-term treatment with pramipexole in restless legs syndrome. Eur. J. Neurol. 2006;13:1306-11	
TX 477	BOE00649842- BOE00649847	2004	Winkelman JW, Johnston L. Augmentation and tolerance with long-term pramipexole treatment of restless legs syndrome (RLS). Sleep Med. 2004;5(1):9-14	
TX 478		2006	Partinen M, Hirvonen K, Jama L, et al. Efficacy and safety of pramipexole in idiopathic restless legs syndrome: a polysomnographic dose-finding study – the PRELUDE study. Sleep Med. 2006;7:407-17	
TX 479		2006	Vignatelli L, Billiard M, Clarenbach P et al. EFNS guidelines on management of restless legs syndrome and periodic limb movement disorder in sleep. Eur. J. Neurol. 2006;13:1049-1065	
TX 480	BOE00881504	12/2006	Overview by Diagnoses	
TX 481		02/08/07	GlaxoSmithKline. Feb. 8, 2007 Press Release; <a href="http://www.gsk.com/investors/reports/gsk_q42006/q42006.pdf">http://www.gsk.com/investors/reports/gsk_q42006/q42006.pdf</a>	
TX 482	BOE00881505		RLS Patient Based Model	
TX 483			U.S. Department of Health and Human Services. Evidence Shows Fibromyalgia Pain Is Real: Experts; <a href="http://www.womenshealth.gov/news/english/536333.htm">http://www.womenshealth.gov/news/english/536333.htm</a>	
TX 484		2003	Holman AJ. Fibromyalgia and Pramipexole: Promise and Precaution. J. Rheumatol. 2003;30:2733	

TX NO.	BATES	DATE	DESCRIPTION	ADMITTED
TX 485		2005	Holman AJ, Myers RR. A Randomized, Double-Blind, Placebo-Controlled Trial of Pramipexole, a Dopamine Agonist, in Patients With Fibromyalgia Receiving Concomitant Medications. <i>Arthritis &amp; Rheum.</i> 2005;52:2495-2505	
TX 486		2000	Corrigan MH, Denahan AQ, Wright CE, Ragnal RJ, Evans DL. Comparison of pramipexole, fluoxetine, and placebo in patients with major depression. <i>Depression and Anxiety.</i> 2000;11(2):58-65	
TX 487		2002	Burn DJ. Beyond the Iron Mask: Towards Better Recognition and Treatment of Depression Associated with Parkinson's Disease. <i>Mov. Disord.</i> 2002;17:445-54	
TX 488		2003	Rektorova I, Rektor I, Bares M, et al. Pramipexole and pergolide in the treatment of depression in Parkinson's disease: a national multicenter prospective randomized study. <i>Eur. J. Neurol.</i> 2003;10:399-406	
TX 489			Curriculum Vitae of Paul A. Bartlett	
TX 491	BOE00882000- BOE00882011	12/17/84	English Translation of BOE00849213-BOE00849224 (TX 40)	
TX 492	BOE00881958- BOE00881965		English Translation of BOE00849171-BOE00849178 (TX 9)	
TX 493	BOE00881978- BOE00881990	09/20/84	English translation of BOE00849191-BOE00849203 (TX 35)	
TX 494	BOE00882012- BOE00882018		English translation for BOE00849164-BOE00849170 (TX 41)	
TX 495	BOE00881966- BOE00881977	05/28/85	English translation of BOE00849179-BOE00849190 (TX 42)	
TX 496	BOE00132270- BOE00132271	09/06/85	Memorandum re SND 919 CL2Y on September 4, 1985	
TX 497	BOE00881956- BOE00881957		English translation of BOE00132270-BOE00132271 (TX 496)	
TX 498	BOE00881991- BOE00881999	10/02/85	English translation of BOE00849204-BOE00849212 (TX 50)	
TX 499	BOE00004167- BOE00004177	1985	Bericht III/1985 – July – September 1985 Report	

TX NO.	BATES	DATE	DESCRIPTION	ADMITTED
TX 500	BOE00881945- BOE00881955	1985	English translation of BOE00004167-BOE00004177 (TX 499)	
TX 501	BOE00004178- BOE00004197	1986	Bericht II/1986 – April – June 1986 Report	
TX 502	BOE00882019- BOE00882038		English translation of BOE00004178-BOE00004197 (TX 501)	
TX 503	BOE00037825- BOE00037861	08/01/88	SND 919 Report by Julian H. Shelley	
TX 504	BOE00754889- BOE00754929		Mirapex Formulary Submission Dossier	
TX 505	BOE00116352	07/1997	First Approval, in USA, for P&U/Boehringer Ingelheim's Mirapex (Market Letter)	
TX 506	BOE00822063- BOE00822083		Article: Restless Legs Syndrome by William Ondo, MD	
TX 507	MYL00000093- MYL00000394	08/06/05	Letter to M. Garcia from S. Talton enclosing "technical sections" of ANDA for Pramipexole Dihydrochloride Tablets	
TX 508	BARR027009- BARR027011		Barr Labs: ANDA Patent Certification and Exclusivity Statement	
TX 509	MYL0003771- MYL0003801	10/26/2005	Letter from S. Bloodworth to M. Morris re Paragraph IV Notification of U.S. Patent No. 4,886,812	
TX 510	MYL00000395- MYL00000877		Section VII Components and Composition Statement Qualitative Compositions and Pharmaceutical Function of Components Pramipexole Dihydrochloride 2.5% Trituration and Pramipexole Dihydrochloride Tablets 0.125MG, 0.25MG, 1MG and 1.5 MG	
TX 511	BARR026502- BARR026505		Barr Labs: ANDA Chemistry, Manufacturing and Controls: Drug Products	
TX 512		03/29/07	Curriculum Vitae of Dr. Mohan Rao	
TX 513		2006	Boehringer Ingelheim 2006 Annual Report	
TX 514	BOE00706138- BOE00706282		Cognos Study # 75 Parkinson's Disease	
TX 515	BOE00761287-	9/25/2005	Pramipexole: Restless Legs Syndrome	

TX NO.	BATES	DATE	DESCRIPTION	ADMITTED
	BOE00761337		Corporate Brand Plan	
TX 516	BOE00846803- BOE00846866		Boehringer Ingelheim: Mirapex Competitor War Game Briefing Packet	
TX 517	BOE00881503		IMS Health, National Sales Perspective: Retail, Non-Ret, NDTI	
TX 518	BOE00881506		IMS Health, National Disease and Therapeutic Index	
TX 519		02/09/07	Letter to Ken Schuler from Jessamyn Berniker re claim terms for construction	
TX 520		12/16/85	English Translation for IV/1985 Quarterly Report BOE00849225-BOE00849236	
TX 521		3/24/2007	"FDA Announces Voluntary Withdrawal of Pergolide Products," <i>FDA News</i> , New Releases P07-54	
TX 522		2005	R. Allen, A. Walters, et al., "Restless Legs Syndrome Prevalence and Impact: REST General Population Study," <i>Archives of Internal Medicine</i> , Volume 165, 2005, p. 1286-92	
TX 523			"Restless Legs Syndrome Fact Sheet," National Institute of Neurological Disorders and Stroke: <a href="http://www.ninds.nih.gov">www.ninds.nih.gov</a>	
TX 524			"Cancer Facts and Figures 2006," American Cancer Society	
TX 525			"All About Diabetes," American Diabetes Association: <a href="http://www.diabetes.org/about-diabetes.jsp">www.diabetes.org/about-diabetes.jsp</a>	
TX 526			M. Silber, et al. "An Algorithm for the Management of Restless Legs Syndrome," <i>Mayo Clinic Proceedings</i> , Vol. 79(7), 2004, p. 916-922	
TX 527	BOE00708678		Statement of Income: Spreadsheet	
TX 528	BARR026065- BARR026068		Barr Laboratories, Inc. Abbreviated New Drug Application Pramipexole Dihydrochloride Tablets, 0.25 mg Basis for the ANDA Submission	
TX 529	BARR022417- BARR022603		Barr Laboratories, Inc. Abbreviated New Drug Application Pramipexole Dihydrochloride Tablets, 0.25 mg Chemistry, Manufacturing and Controls: Drug Substance	
TX 530	BARR022131- BARR022287		Barr Laboratories, Inc. Abbreviated New Drug Application Pramipexole Dihydrochloride Tablets, 0.25 mg Bioavailability/Bioequivalence Summary	
TX 531	BARR027070- BARR027073		Barr Laboratories, Inc. Abbreviated New Drug Application Pramipexole Dihydrochloride Tablets, 0.25 mg Amendment for addition of 0.125mg, 0.5 mg, 1 mg, and 1.5 mg strengths	

TX NO.	BATES	DATE	DESCRIPTION	ADMITTED
TX 532	BARR026530- BARR026651		Basis for the ANDA Submission Barr Laboratories, Inc. Abbreviated New Drug Application Pramipexole Dihydrochloride Tablets, 0.25 mg Amendment for addition of 0.125 mg, 0.5 mg, 1 mg, and 1.5 mg strengths Bioavailability/Bioequivalence General Information	
TX 533	BARR042894- BARR042946		Barr Laboratories, Inc. Abbreviated New Drug Application Pramipexole Dihydrochloride Tablets, 0.25 mg Amendment for addition of 0.125 mg, 0.5 mg, 1 mg, and 1.5 mg strengths Comparison between Last Submitted and Proposed Labeling	
TX 534	BARR045496- BARR045572		Barr Laboratories, Inc. Abbreviated New Drug Application Pramipexole Dihydrochloride Tablets, 0.25 mg Comparison between Generic Drug and Reference Listed Drug	
TX 535	MYL0002161- MYL0002175		Pramipexole Dihydrochloride Tablets 0.125 mg Side by Side Comparison of the Bottle Label	
TX 536		09/29/06	Letter to Joel Neckers from David Harth re Mylan's interest in litigation	
TX 537	BOE00650147- BOE00650169		Article: Prospective Study of Periodic Leg Movements in Prepubertal Children with Sleep Complaints	
TX 538	BOE00673350- BOE00673353	02/27/01	Certified copy of U.S. Patent 6,194,445 Oertel, et al.	
TX 539	BOE00673354- BOE00673357	12/14/99	Use of Pramipexole in the Treatment of Restless Legs Syndrome Certified Copy of U.S. Patent 6,001,861 Oertel et al.	
TX 540	BOE00879936- BOE00879938	02/20/01	The Use of Pramipexole in the Treatment of Restless Legs Syndrome Certified copy of U.S. Patent 6,191,153 Hammer et al.	
TX 542		06/15/04	Use of 2-Amino-6-N-Propyl-Amino-4,5,6,7-Tetrahydrobenzothiazole as a pharmaceutical Composition Having an Antidepressant Activity Certified Copy of U.S. Patent 6,750,235 Rosenbaum Pramipexole as a Treatment for Cocaine Craving	
TX 543		07/22/97	Certified copy U.S. Patent 5,650,420 Hall et al. Pramipexole as a Neuroprotective Agent	
TX 544		10/09/01	Certified copy of U.S. Patent 6,300,365 Holman Use of Dopamine D2/D3 Receptor Agonists to Treat Fibromyalgia	

TX NO.	BATES	DATE	DESCRIPTION	ADMITTED
TX 545	BOE00649690- BOE00649708		Presentation: Boehringer Ingelheim Slides on LCM	
TX 546	BOE00001459- BOE00001479	10/15/02	Transition Agreement between Boehringer Ingelheim International GmbH and Pfizer Inc.	



**CERTIFICATE OF SERVICE**

I, Maryellen Noreika, hereby certify that on March 10, 2008, I electronically filed the foregoing document with the Clerk of the Court using CM/ECF, which will send notification of such filing to the following:

Mary B. Matterer  
MORRIS JAMES LLP

Adam Wyatt Poff  
YOUNG, CONAWAY, STARGATT & TAYLOR LLP

I further certify that copies of the foregoing document were also served upon the following in the manner indicated:

**BY ELECTRONIC MAIL and HAND DELIVERY**

Mary B. Matterer, Esquire  
MORRIS JAMES LLP  
500 Delaware Avenue  
Wilmington, DE 19801

Adam Wyatt Poff, Esquire  
YOUNG, CONAWAY, STARGATT & TAYLOR LLP  
The Brandywine Building  
1000 West Street, 17<sup>th</sup> Floor  
Wilmington, DE 19801

**BY ELECTRONIC MAIL**

Glenn J. Pfadenhauer, Esquire  
Jessamyn S. Berniker, Esquire  
Dov P. Grossman, Esquire  
WILLIAMS & CONNOLLY LLP  
725 Twelfth Street, N.W.  
Washington, DC 20005-5901

Shannon M. Bloodworth, Esquire  
HELLER EHRMAN LLP  
1717 Rhode Island Ave., NW  
Washington, DC 20036

David J. Harth, Esquire  
HELLER EHRMAN LLP  
One East Main Street, Suite 201  
Madison, WI 53703

*/s/ Maryellen Noreika*

---

Maryellen Noreika (#3208)